Biosearch Technologies Issued Two new Patents
News Mar 09, 2010
Biosearch Technologies, Inc. has announced that it has been awarded U.S. Patent Nos. 7635598 and 7635762. These patents demonstrate Biosearch’s continued commitment to the advancement in the field of pro-fluorescent assays.
“Luminescent Metal Ion Complexes” (US7635762), developed by Ronald Cook, Matthew Lyttle, and Mary Katherine Johansson, describes how a non-traditional fluorophore composed of a metal ion chelate can be efficiently attached to a biomolecule. This technology was used to develop Biosearch’s Pulsar® 650 reporter label, notable for its large Stokes’ Shift (absorption maximum at 450 nm; emission maximum at 650nm).
“Inducible fluorescence assay” (US7635762), developed by Ronald Cook, Eliana Saxon Armstrong, and Hans E. Johansson, describes a novel reporter system based on the use of an azoreductase enzyme to permanently destroy the quenching ability of Biosearch’s BHQ® dyes, thereby activating any linked fluorophore. The versatility of the new assays system in this invention dramatically expands the ability to perform multiplexed, cell-based reporter gene assays used in high throughput screening.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE